- Home
- PSBD vs MREO Comparison
PSBD vs MREO Comparison
Compare PSBD & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSBD
- MREO
- Stock Information
- Founded
- PSBD 2009
- MREO 2015
- Country
- PSBD United States
- MREO United Kingdom
- Employees
- PSBD N/A
- MREO N/A
- Industry
- PSBD
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- PSBD
- MREO Health Care
- Exchange
- PSBD Nasdaq
- MREO Nasdaq
- Market Cap
- PSBD 452.6M
- MREO 424.5M
- IPO Year
- PSBD 2024
- MREO N/A
- Fundamental
- Price
- PSBD $14.48
- MREO $2.85
- Analyst Decision
- PSBD Buy
- MREO Strong Buy
- Analyst Count
- PSBD 4
- MREO 7
- Target Price
- PSBD $14.13
- MREO $7.71
- AVG Volume (30 Days)
- PSBD 42.8K
- MREO 1.2M
- Earning Date
- PSBD 08-07-2025
- MREO 08-12-2025
- Dividend Yield
- PSBD 11.72%
- MREO N/A
- EPS Growth
- PSBD N/A
- MREO N/A
- EPS
- PSBD N/A
- MREO N/A
- Revenue
- PSBD N/A
- MREO N/A
- Revenue This Year
- PSBD N/A
- MREO N/A
- Revenue Next Year
- PSBD N/A
- MREO $54.07
- P/E Ratio
- PSBD N/A
- MREO N/A
- Revenue Growth
- PSBD N/A
- MREO N/A
- 52 Week Low
- PSBD $11.51
- MREO $1.58
- 52 Week High
- PSBD $16.85
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- PSBD 69.09
- MREO 64.74
- Support Level
- PSBD $13.80
- MREO $2.61
- Resistance Level
- PSBD $14.68
- MREO $2.85
- Average True Range (ATR)
- PSBD 0.27
- MREO 0.17
- MACD
- PSBD 0.04
- MREO 0.03
- Stochastic Oscillator
- PSBD 80.44
- MREO 88.83
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).